United Therapeutics Corporation (UTHR) Cash Flow Statement

The wide quarterly swings in OCF/NI, from 0.62 to 1.69, suggest that working capital changes, particularly receivables and inventory, are driving cash flow timing rather than fundamental profitability. The negative working capital changes in 2025Q2 and 2026Q2 (e.g., -$203.0M and -$124.1M) likely reflect channel dynamics or payment timing, which may normalize over time. Investors should monitor whether these swings persist, as they could indicate aggressive revenue recognition or inventory build-up.

The FCF margin volatility is driven by both capex intensity and working capital swings, with capex peaking at 26.3% of revenue in 2025Q3. Despite this, cumulative FCF of approximately $2.7B over the period underscores the company's ability to generate substantial cash, even as growth decelerates. The recent dip in FCF margin to 26.2% in 2026Q2, coupled with rising capex, suggests a deliberate investment phase that may pressure near-term FCF but could support long-term growth.

The doubling of capex as a percentage of revenue suggests UTHR is investing heavily in manufacturing capacity or infrastructure, likely to support Tyvaso DPI expansion and organ manufacturing initiatives. This elevated capex, if sustained, could compress FCF margins, but the company's high gross margins and fortress balance sheet provide ample cushion. Investors should assess whether this investment is maintenance-driven or growth-oriented, as the latter could yield long-term returns.

The extreme volatility in working capital changes, with negative readings in four of the last ten quarters, suggests that UTHR's cash flow is heavily influenced by the timing of receivables and inventory, particularly around product launches like Tyvaso DPI. These swings may obscure underlying operational performance, but the company's ability to generate positive OCF in all quarters indicates a resilient business model. Investors should monitor whether these swings become more pronounced as the franchise matures.

The $3.6B in buybacks, including $1.5B in 2026Q1 and $1.0B in 2025Q3, demonstrates management's confidence in the business and a commitment to shareholder returns. However, this aggressive deployment, combined with rising capex and R&D, may strain liquidity if cash flows weaken. The lack of dividends suggests a focus on capital appreciation, but investors should weigh the opportunity cost of these buybacks versus potential M&A or pipeline diversification.